Episode 25: Treatment Revolution in Iga Nephropathy
Join Dana Rizk, MD (University of Alabama at Birmingham, USA), and Shikha Wadhwani, MD (Indiana University School of Medicine, USA), for a conversation on the treatment revolution in IgAN. They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care. Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.This podcast was supported by Travere.
--------
14:30
--------
14:30
Episode 24: Overview of the Latest Guidance in IgA Nephropathy Management
Join Dana Rizk, MD (University of Alabama at Birmingham, United States), and Brad Rovin, MD (Ohio State University, United States), Co-Chair of the 2025 KDIGO IgAN/IgAV Guideline, for a deep dive into the latest updates in patient care. Their conversation explores the most important takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals designed to improve outcomes.This podcast was supported by Travere.
--------
19:00
--------
19:00
Episode 23: A Patient and Caregiver Perspective
What does life with a rare kidney disease really look like?Marianne Silkjaer Nielsen (Founder of CompCure, Denmark) offers a powerful voice for patients and caregivers. She reflects on the long diagnostic journey, the challenges of managing rare kidney disease, and the need for better awareness, advocacy, and international registries to improve outcomes.This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).This series was supported by Apellis and Sobi.
--------
12:15
--------
12:15
Episode 22: Advancing Research and Novel Therapies for C3G
What does the future of treatment for C3 Glomerulopathy (C3G) look like? Dr. Nicole van de Kar (Radboud University Medical Center, The Netherlands) unpacks the pathophysiology of C3G, from genetic and autoantibody factors to the central role of the alternative pathway. She explores the limits of current C5 therapies and the potential of new strategies targeting C3 activation that could reshape patient care worldwide. This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).This series was supported by Apellis and Sobi.
--------
23:15
--------
23:15
Episode 21: Diagnosis and Management of C3G
How do patients with C3 Glomerulopathy (C3G) present, and why is confirming the diagnosis so complex? Dr. David Kavanagh (National Renal Complement Therapeutics Centre, United Kingdom) walks through the diagnostic process, the shortcomings of traditional immunosuppression, and the promise of emerging therapies like alternative pathway inhibitors. He also tackles one of the toughest challenges: managing post-transplant recurrence.This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).This series was supported by Apellis and Sobi.
Ouça KDIGO Conversations in Nephrology, Isso não é uma sessão de análise, com Vera Iaconelli e muitos outros podcasts de todo o mundo com o aplicativo o radio.net
Brasil